Literature DB >> 3662474

Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections.

W J Rodriguez1, R H Bui, J D Connor, H W Kim, C D Brandt, R H Parrott, B Burch, J Mace.   

Abstract

The potential exposure to ribavirin aerosol in the environment was assessed in nurses caring for infants and children with severe lower respiratory tract infections due to respiratory syncytial virus. Ribavirin aerosol was administered via a ventilator, oxygen tent, or oxygen hood. Participants worked directly with infants receiving ribavirin for 20.0 to 35.0 h over a 3-day period. No toxic or adverse effects of ribavirin aerosol were observed in any of the 19 nurses studied, and ribavirin was not detected in erythrocytes, plasma, or urine collected after the potential exposure period.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662474      PMCID: PMC174887          DOI: 10.1128/AAC.31.7.1143

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  If nothing goes wrong, is everything all right? Interpreting zero numerators.

Authors:  J A Hanley; A Lippman-Hand
Journal:  JAMA       Date:  1983-04-01       Impact factor: 56.272

Review 2.  Ribavirin: a clinical overview.

Authors:  H Fernandez; G Banks; R Smith
Journal:  Eur J Epidemiol       Date:  1986-03       Impact factor: 8.082

3.  Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease.

Authors:  W J Rodriguez; H W Kim; C D Brandt; R J Fink; P R Getson; J Arrobio; T M Murphy; V McCarthy; R H Parrott
Journal:  Pediatr Infect Dis J       Date:  1987-02       Impact factor: 2.129

4.  Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease.

Authors:  C B Hall; J T McBride; C L Gala; S W Hildreth; K C Schnabel
Journal:  JAMA       Date:  1985-12-06       Impact factor: 56.272

5.  Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

Authors:  B E Gilbert; S Z Wilson; V Knight; R B Couch; J M Quarles; L Dure; N Hayes; G Willis
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

  5 in total
  8 in total

1.  Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1991-02-01       Impact factor: 8.262

2.  Ribavirin aerosol therapy: safety for staff.

Authors:  R A Bortolussi; R Gold
Journal:  CMAJ       Date:  1988-02-01       Impact factor: 8.262

3.  Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

Authors:  D M Lewinsohn; R A Bowden; D Mattson; S W Crawford
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections.

Authors:  J S Bradley; J D Connor; L S Compogiannis; L L Eiger
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

5.  Ribavirin small-particle-aerosol treatment of influenza B virus infection.

Authors:  D I Bernstein; P D Reuman; J R Sherwood; E C Young; G M Schiff
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Pregnancy outcome after exposure to injectable ribavirin during embryogenesis.

Authors:  Massoud Rezvani; Gideon Koren
Journal:  Reprod Toxicol       Date:  2005-08-24       Impact factor: 3.143

7.  Novel insights into human respiratory syncytial virus-host factor interactions through integrated proteomics and transcriptomics analysis.

Authors:  Clyde Dapat; Hitoshi Oshitani
Journal:  Expert Rev Anti Infect Ther       Date:  2016-02-03       Impact factor: 5.091

8.  Antiviral agents against respiratory viruses.

Authors:  Cecile L Tremblay
Journal:  Clin Microbiol Newsl       Date:  2001-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.